HOME >> MEDICINE >> NEWS
NOVANTRONE application for multiple sclerosis granted priority review by FDA

FDA review of NOVANTRONE data to be completed within six months

SEATTLE-Immunex Corporation (NASDAQ:IMNX) announced today that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the new drug application (NDA) for NOVANTRONER (mitoxantrone for injection concentrate), indicating that the FDA will act on the application within six months of its date of submission. Immunex filed for expanded labeling for NOVANTRONE for the treatment of patients with secondary progressive multiple sclerosis (MS) on June 7, 1999.

"This is an important milestone in the development of NOVANTRONE as a potential treatment for people with secondary progressive MS," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "We will continue to work closely with the FDA over the next six months as they evaluate these data."

The results of the pivotal NOVANTRONE Phase III study showed that NOVANTRONE had a statistically significant impact on reduction of relapse rate and delay in disability progression in patients with secondary progressive MS. Additional follow-up data presented at a recent international conference showed that one year after treatment was stopped, patients treated with NOVANTRONE continued to experience a reduction in their number of attacks, and a delay in their disability progression.

In the study, treatment with NOVANTRONE resulted in generally manageable side effects that were primarily mild to moderate. During the two-year trial, the most frequent side effects reported by patients treated in the 12 mg/m2 arm were nausea, alopecia (hair loss), upper respiratory tract infection, urinary tract infection, menstrual disorder, and transient neutropenia (a reduced number of white blood cells).

Multiple sclerosis is a chronic, debilitating disease of the central nervous system that, in its various stages, afflicts as many as 350,000 people in the Unit
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
19-Jul-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Considerable reductions in radiation exposure possible with 16-MDCT scanner on body applications
3. AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
4. Roche files marketing application for Avastin with European health authorities
5. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Research suggests possible blood test for multiple sclerosis
8. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma
9. Good fats decrease multiple heart disease risk factors
10. Swallowing multiple magnets poses danger to children
11. Sleep disorders often indicate multiple health conditions

Post Your Comments:
(Date:7/29/2015)... ... July 30, 2015 , ... Macro Wealth Management ... through the Smile for a Lifetime program by encouraging their clients to donate their ... by MWM Presidents Dr. Mart McClellan and Tim Streid, who see charitable giving as ...
(Date:7/29/2015)... ... July 30, 2015 , ... In their continuing drive ... of online continuing education courses for Athletic Trainers , HomeCEUConnection.com, today announced ... and Education Sports Medicine Series. , The new online continuing education courses were ...
(Date:7/29/2015)... ... July 29, 2015 , ... If you’re a fan of Vietnamese banh mi ... by the Orange County Register , more than 465,000 pounds of mislabeled meat ... article does not mention any reported illnesses that have been connected to problems reportedly ...
(Date:7/29/2015)... ... 2015 , ... Sports fans young and old at the National Cherry Festival ... Detroit Lions, joined by A Forever Recovery, a holistic treatment center for substance abuse ... Pro Bowl Offensive Lineman Lomas Brown, and Tight End Rob Rubick signed foam footballs, ...
(Date:7/29/2015)... ... July 29, 2015 , ... Conventional theories used by economists for the ... may be able to unlock mysteries about the behavior of microbial life on earth, ... and Columbia University. , The findings, published July 29 in the open access journal ...
Breaking Medicine News(10 mins):Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Three Important Product Liability Realities Offered In Light of News of Recent Product Recalls 2Health News:Three Important Product Liability Realities Offered In Light of News of Recent Product Recalls 3Health News:A Forever Recovery Holds Autograph Event with Former Detroit Lions at Cherry Festival 2Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 2Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 3
(Date:7/29/2015)... 29, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that it will release ... 10, 2015 after the close of the U.S. financial ... webcast on Monday, August 10, 2015 at 4:30 p.m. ... and corporate developments. For both "listen-only" participants ...
(Date:7/29/2015)... 29, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... Board of Directors, after careful consideration and with ... advisors, has unanimously rejected the purported revised, highly ... plc (NASDAQ: HZNP ) ("Horizon") to acquire ... an all-stock transaction (the "July 21 Proposal"). ...
(Date:7/29/2015)... 29, 2015 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... up to $21.5 million through two financing agreements. The ... ) ("Hercules"), for a term loan of up to ... Growth Fund ("Discover"), for the sale to Discover of ... Stock") for up to $12 million in gross proceeds ...
Breaking Medicine Technology:Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 3Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 4Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 5Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 6Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 7
Cached News: